CN1434042A - Cattail pollen extract and preparation process and use thereof - Google Patents
Cattail pollen extract and preparation process and use thereof Download PDFInfo
- Publication number
- CN1434042A CN1434042A CN 03115508 CN03115508A CN1434042A CN 1434042 A CN1434042 A CN 1434042A CN 03115508 CN03115508 CN 03115508 CN 03115508 A CN03115508 A CN 03115508A CN 1434042 A CN1434042 A CN 1434042A
- Authority
- CN
- China
- Prior art keywords
- pollen tyjphae
- tyjphae extract
- ethanol
- pollen
- myocardial ischemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a cattail pollen extract, its preparation method and its application. Its preparation method includes the following steps: using aqueous ethyl alcohol to make thermal extraction of typha poller, and adopting macroporous resin adsorption chromatographic process to obtain the invented typha pollen extract whose total flavone content is up to 50%. The animal tests show that it can obviously reduce extent of myocardial ischemia after ligation of canine coronary artery, can reduce the range of myocardial ischemia, can obviously reduce infarct range and can obviously reduce myocardial oxygen consumption, etc. so that it can be used for preparing medicine or food for preventing and curing angio cardiopathy due to myocardial ischemia.
Description
Technical field:
The present invention relates to medical technical field, is Pollen Tyjphae extract and preparation method thereof and the purposes that Pollen Tyjphae extract is used to prepare control myocardial ischemia cardiovascular disease medicine or food.
Background technology:
Cattail pollen is medicinal herbs most in use, derives from the pollen of Typhaceae Typhaceae typha Typha L. raupo cattail Typhaangustifolia L., various plants such as typha angustata Typha angustata Bory et Chaub, common cattail T.latifolia L..Another name cattail's spike pollen, stem or leaf of cattail Huang etc.Its medicinal history is long, and the Han dynasty Shennong's Herbal is classified as top grade.Have hemostasis, stagnation resolvation, treating stranguria effect.Be used for spitting blood, bleeding from five sense organs or subcutaneous tissue, spitting of blood, uterine bleeding, traumatic hemorrhage, amenorrhoea is stimulated the menstrual flow, gastral cavity ventral spine pain, tumbling and swelling, blood strangury and dry pain.Compendium of Material Medica record: " the cattail pollen brothers faint cloudy blood system medicine also, thus can control blood and relieving pain, living then can manage it, ripely then can end, with the same usefulness of Trogopterus Dung, can control all pains of all trusted subordinates "." the chest spleen " that motherland's medical science is described, " angina pectoris ", its syndrome is similar to coronary heart disease and angina pectoris, according to clinical report, by cattail pollen and Trogopterus Dung is that main " Powder for Dissipating Blood Stasis " formed adds flavor coronary heart disease is had certain curative effect, in addition, Recent study finds that the single cattail pollen has microcirculation improvement, control rabbit experiment atherosclerosis (AS), blood fat reducing and the effect that alleviates the AS patch are arranged, and can reduce the serum cholesterol level of hyperlipidemia patient, reduce platelet adhesion rate and aggregation rate and improve the effects such as clinical symptom of coronary heart disease, and toxic side effect is few, and is safe in utilization.Cattail pollen mainly contain steroid class, flavonoid, long-chain fat hydrocarbon compound, amino acids, inorganic components etc. (1, Botany Gazette, 1990,32 (2): 137; 2, Chinese Pharmaceutical Journal, 1998,33 (10): 587; 3, Thrombosis Research, 1990,57 (6): 957; 4, herbal medicine, 1998,27 (11): 693).So far do not see relevant report with Pollen Tyjphae extract control myocardial ischemia cardiovascular disorder.
Summary of the invention:
The invention provides a kind of Pollen Tyjphae extract and preparation method thereof.
Preparation method of the present invention is as follows:
Cattail pollen after extracting with the aqueous ethanol heating concentrates extracting solution, and centrifuged supernatant or filtrate are got in the centrifugal or filtration of concentrated solution; Centrifuged supernatant or filtrate are used macroporous resin adsorption, remove impurity with water wash earlier, use moisture lower alcohol wash-out again; The lower alcohol elutriant is concentrated into certain volume, uses the ethanol alcohol precipitation, removes precipitation earlier, and reconcentration is to doing or remove spraying drying behind the ethanol, Pollen Tyjphae extract.
[Pollen Tyjphae extract chemical composition analysis]
Pollen Tyjphae extract obtains 5 compounds by reverse-phase chromatography carrier column chromatographys such as silica gel, sephadexLH-20, ODS: 1, Quercetin-3,3 '-dme; 2, Quercetin-3,3 '-dme-4 '-O-β-D-glucopyranoside; 3, Isorhamnetol-rich lactoside of 3-O-β-D-; 4, Isorhamnetol-3-O-neohesperidoside; 5, typhaneoside.Measure through chemistry, spectral method, the chemical structure of general formula of first three compound is as follows:
Wherein:
Work as R
1=CH
3, R
2=H, R
3=CH
3The time, its be Quercetin-3,3 '-dme;
Work as R
1=CH
3, R
2=Glu (glucose), R
3=CH
3The time, its be Quercetin-3,3 '-dme-4 '-O-β--D-glucopyranoside
Work as R
1=Gala (semi-lactosi), R
2=H, R
3=CH
3The time, it is Isorhamnetol-3-O-β-D-galactoside
The chemical structural formula of all the other 2 compounds is:
Isorhamnetol-3-O-neohesperidoside typhaneoside
This shows that Pollen Tyjphae extract is the mixture of flavones ingredient.Show that with the HPLC quantitative analysis it mainly contains Isorhamnetol-3-O-β-D-galactoside, Isorhamnetol-3-O-neohesperidoside, typhaneoside, three's content accounts for more than 40% of general extractive.Use determined by ultraviolet spectrophotometry, general flavone content accounts for more than 50% of general extractive.Through experimentation on animals, Pollen Tyjphae extract can effectively be prevented and treated the myocardial ischemia cardiovascular disorder.
Description of drawings:
Fig. 1 is the graphic representation of Pollen Tyjphae extract to dog coronary ligation epicardial electrogram ST section summation (∑ ST) influence
Fig. 2 is the graphic representation of Pollen Tyjphae extract to dog coronary ligation myocardial infarct size (N-ST) influence
Fig. 3 is that Pollen Tyjphae extract is to dog myocardial consumption of oxygen (ml/min.100g
-1) influence graphic representation
Fig. 4 is the graphic representation of Pollen Tyjphae extract to dog cardiac muscle oxygen uptake rate (%) influence
Fig. 5 is the graphic representation of Pollen Tyjphae extract to dog coronary flow (ml/min) influence
Embodiment:
The preparation of Pollen Tyjphae extract: cattail pollen is carried 2 times with 40～95% ethanol heat, and each solvent consumption is about 4～12 times of crude drug amount; Concentrate the centrifugal or filtration of concentrated solution behind the united extraction liquid; Supernatant liquor or filtered liquid are passed through macroporous resin adsorption, and macroporous resin as D101, D201, ZTC-1, AB-8,1300-1 type macroporous resin etc., with water wash is removed impurity earlier for being the polystyrene type porousness polymeric adsorbent of bridging materials with vinylbenzene; Use moisture lower alcohol wash-out again, lower alcohol is C such as methyl alcohol, ethanol or propyl alcohol
1～C
5Alcohols, concentration is 40～95%, make a living 5～15 times of dose of consumption; Collect the lower alcohol elutriant, concentrate the back and use the ethanol alcohol precipitation, making the ethanol final concentration is 70～95%; Supernatant concentration behind the alcohol precipitation is to doing, Pollen Tyjphae extract of the present invention, standby after the drying and crushing, product yield more than 1.0% of dose of making a living.
Embodiment 1
100 kilograms of cattail pollens drop into extractor, soak 24 hours with 100 liter of 70% alcohol at normal temperature, boil for 800 liters with 70% ethanol successively at 90～100 ℃ and to carry 3 times, each extraction time is 2 hours, merges No. 3 times extracting solution, be concentrated into 50 liters, filter, filtrate is adjusted to 100 liters with distilled water.Slowly by the adsorption column of 200 liters of ZTC-1 type macroporous resins (Tianjin became clarification technique company limited to produce in positive day) is housed, remove impurity again with 1000 liters of distilled water drip washing; Use 1000 liter of 70% ethanol elution again, collect elutriant, be concentrated into 10 liters, under agitation slowly add 100 liter of 95% ethanol, finish, left standstill 12 hours, the centrifugal precipitation of abandoning, supernatant concentration is to doing, and further drying is also pulverized, 1.8 kilograms of the Pollen Tyjphae extracts of yellow powder shape, be 1.8% by crude drug amount yield.Biological activity determination
Adopt the anesthetized dog myocardial infarction model, observe Pollen Tyjphae extract of the present invention the therapeutic action of acute myocardial infarction model and the influence of myocardial consumption of oxygen.Concrete experimental technique is as follows:
One, Pollen Tyjphae extract causes the therapeutic action of acute myocardial infarction model to the anesthetized dog coronary artery ligation
1 materials and methods
1.1 animal
Healthy hybrid dog is provided by the The 2nd Army Medical College animal center, animal rearing conformity certification number: the moving word of medical officer D2001-31 number.Male female dual-purpose.Body weight 10～14kg.Article 18, dog is divided into 3 groups at random, 6 every group.
1.2 dosage is provided with grouping and sees Table 1 with dosage,
Table 1 experiment grouping and dosage regimen group route of administration dosage number of animals (bar) physiological saline control group are oral, single-dose 1ml/kg 6 Radix Salviae Miltiorrhizae Tabellae groups are oral, 1/kg of single-dose, 6 Pollen Tyjphae extract groups are oral, single-dose 8mg/kg 6
1.3 method
The mensuration of dog acute myocardial ischemia model copy and epicardial electrogram with reference to the methodology of pharmacological evaluation [chief editor such as Xu Shuyun. pharmacological experimental methodology (third edition). the 8th piece: the medicine for cardiovascular system laboratory method.Beijing: People's Health Publisher, 2002:1054].Place " multiple spot is fixed " epicardial lead and fixing, the epicardial lead of 30 points of mapping at model dog heart surface.Signal is by PowerLab data logging analytical system (ML785/8S, AD Instruments, Australia) be connected on the real time record computer, the summation of lead number and ST section lift-off value that the different time points epicardial electrogram ST section of computational rules raises is used degree and the scope of understanding myocardial ischemia.
Ligation dirty the weighing of coring after 3 hours, dyeing, infarcted region is not painted, and non-infarcted region black, cuts off coloured part, and uncoloured infarcted region is weighed.Respectively got blood 3ml in 3 hours before the coronary ligation and after the administration, get serum and survey creatine creatase CK and lactic acid LDH from right ventricle.
Test-results is represented with x ± S, carries out variance analysis with the SPSS statistical software, relatively the significance that differs between each group.
2 results
2.1 the influence of degree of myocardial ischemia (epicardial electrogram ∑ ST) be the results are shown in Table 2 and Fig. 1
Table 2 Pollen Tyjphae extract is to the influence of dog coronary ligation epicardial electrogram ST section summation (∑ ST)
(mV, x ± s, n=6/group)
Organize administration after the administration
The not front 15min 30min 60min 90min 120min 180min of dosage guideline gives birth to 1 x ± s 220.3 238.3 ± 269.0 ± 289.3 ± 301.2 ± 274.7 ± 259.0 ± reason ml/kg ± 65.7 54.2 44.1 49.4 49.5 84.2 67.5 salt solution
Change red 1 x ± s 221.8 176.8 ± 146.0 ± 222.7 ± 90.2 242.8 ± 242.7 ± 227.8 ± ginseng/kg ± 61.1 64.5 39.5, % 10.5 ± 10.1 27.4 ± 24.4 36.0 ± 19.5 43.7 ± 31.5 26.2 ± 21.3 19.9 ± 19.1
* *110.1 122.4 106.0
Change %-22.2 ±-33.5 ±-1.9 ± 7.6 ± 30.0 5.7 ± 30.6 0.2 ± 26.5
9.2
* *8.6
* *20.2
* *Pu 8mg/k x ± s 207.8 137.2 ± 140.4 ± 148.8 ± 149.8 ± 143.0 ± 39.8 144.4 ± 36.7 yellow g ± 29.5 66.2 46.4
* *37.9
*28.9
*
Variation %-35.4 ±-33.7 ±-29.1 ±-27.6 ±-30.4 ±-28.9 ±
24.5
*** 13.8
*** 11.1
*** 12.4
*** 19.6
*** 20.7
***
*P＜0.05,
* *Compare with the physiological saline group P＜0.01
Found out that by table 2 and Fig. 1 behind the coronary ligation 15 minutes, the outer electrograph ST section summation (∑ ST) of the physiological saline control group heart obviously raise, ∑ ST raises and reaches 301.2 ± 49.5 during to 90 minutes (min), after this slowly falls after rise; Can alleviate degree of myocardial ischemia behind the Pollen Tyjphae extract group 8mg/kg gastric infusion, ∑ ST significantly descends, and effect continued to 180 minutes in 15 minutes from administration, and more all there were significant differences for each time point and physiological saline group (P＜0.01).Positive control Radix Salviae Miltiorrhizae Tabellae group after administration 15 minutes to 60 minutes, ∑ ST descends, with the physiological saline group with time point comparing difference significantly (P＜0.01), but after 60 minutes to 180 minutes with physiological saline group there was no significant difference.
2.2, the results are shown in Table 3 and Fig. 2 to the influence of myocardial ischemia scope (epicardial electrogram N-ST)
Table 3 Pollen Tyjphae extract is to the influence of dog coronary ligation myocardial infarct size (N-ST)
(counting x ± s, n=6/group)
Organize administration after the administration
The not front 15min 30min 60min 90min 120min 180min of dosage guideline gives birth to 1 x ± s 27.3 ± 28.0 ± 1.8 29.2 ± 1.0 29.7 ± 0.5 29.5 ± 0.8 27.8 ± 2.4 26.8 ± 2.7 reason ml/kg, 1.8 salt and changes red 1 x of % 2.5 ± 3.0 7.0 ± 6.2 8.9 ± 7.0 8.2 ± 5.3 1.8 ± 4.4-1.9 ± 6.0 water ± s 28.0 ± 24.7 ± 4.5 22.8 ± 23.8 ± 4.7*25.8 ± 4.7 25.3 ± 4.1 24.5 ± 3.8 ginseng sheet/kg 1.7 2.9
* *Sheet changes %-12.0 ± 13.7-18.5 ±-15.0 ±-7.5 ± 17.6-9.3 ± 15.3-12.5 ± 12.4
8.6
* *15.8
* *Pu 8mg/ x ± s 28.0 ± 24.0 ± 4.9 22.8 ± 22.7 ± 23.5 ± 3.2
*22.5 ± 4.7 22.8 ± 5.0 yellow kg 1.4 4.1
* *3.6
* *
Change %-14.7 ± 14.4-18.7 ±-19.2 ±-16.1 ±-19.6 ±-18.4 ± 18.2
12.1
* *10.6
* *10.2
* *17.3
* *P＜0.05,
* *Compare with the change value of physiological saline group with time point P＜0.01
Find out that by table 3 and Fig. 2 Pollen Tyjphae extract 8mg/kg can significantly dwindle myocardial ischemia scope (P＜0.01), reduce the N-ST value, act on sustainable 120 minutes.The positive control drug Radix Salviae Miltiorrhizae Tabellae after administration 30 minutes one 60 minutes myocardial ischemia scopes and physiological saline group with time point relatively highly significant descend (P＜0.01), but from 90 minutes with physiological saline group there was no significant difference, rapid-action and action time short.
2.3 the quantitative tissue to the myocardial infarct size influence is learned detection, the results are shown in Table 4
Table 4 Pollen Tyjphae extract is to the influence of N-BT dyeing mensuration myocardial infarct size
1/the kg of (%) infarct/left ventricle (%) physiological saline 1ml/kg 12.10 ± 2.28 23.24 ± 1.97 Radix Salviae Miltiorrhizae Tabellae 9.29 ± 0.96 of (x ± s, n=6 only/group) group dosage infarct/whole-heartedly
*17.16 ± 3.24
* *Pollen Tyjphae extract 8mg/kg 9.71 ± 1.02
*18.69 ± 1.59
*
*P＜0.05,
* *Compare with the physiological saline group P＜0.01
Find out that by table 4 Pollen Tyjphae extract 8mg/kg gastric infusion can significantly reduce myocardial infarct size.Pollen Tyjphae extract infarct/the ratio whole-heartedly and the ratio of infarct/left ventricle and the physiological saline group highly significant (P＜0.01) that relatively descends.Positive controls, Pollen Tyjphae extract group all can be dwindled myocardial infarct size (P＜0.01) significantly.
2.4 Pollen Tyjphae extract to coronary ligation after the influence of serum biochemistry index, the results are shown in Table 5
Table 5 Pollen Tyjphae extract is to the influence of coronary ligation dog right ventricle serum biochemistry index
(x ± s, n=6/group) PROJECT TIME physiological saline 1ml/kg Radix Salviae Miltiorrhizae Tabellae 1/kg Pollen Tyjphae extract 8mg/kgCK (U/I) administration preceding 149.76 ± 15.14 149.76 ± 20.95 125.47 ± 11.16
After the administration 615.22 ± 45.51
△ △ △392.51 ± 57.73
* * △ △ △442.53 ± 50.85
* * △ △ △After LDH administration preceding 367.98 ± 68.45 404.39 ± 47.48 436.85 ± 98.37 (IU/L) administration 959.21 ± 109.21
△ △ △776.67 ± 68.13
* * △ △ △807.46 ± 132.87
* △ △ △ *P＜0.05,
* *Compare with the physiological saline group P＜0.01;
△ △P＜0.05,
△ △ △P＜0.01 is relatively preceding with administration
Find out by table 5, respectively organize serum creatine creatase CK after the coronary artery ligation and lactic acid LDH all raises.Pollen Tyjphae extract 8mg/kg and positive control drug Radix Salviae Miltiorrhizae Tabellae be the rising degree (P＜0.01) of the reduction serum creatine kinase of energy highly significant all; Pollen Tyjphae extract and positive control drug can also significantly reduce the rising degree (P＜0.01) of right ventricle arterial blood serum lactic acid.
Experimental result shows; the Pollen Tyjphae extract gastric infusion can significantly reduce the degree of the myocardial ischemia of coronary ligation dog; dwindle the myocardial ischemia scope; it is consistent that quantitative tissue is learned the result who detects with epicardial electrogram mensuration; compare with the physiological saline control group; infarct significantly dwindles; the Acute Myocardial Infarction that proof Pollen Tyjphae extract gastric infusion causes the dog coronary artery ligation has the obvious treatment effect; experimental result also shows; Pollen Tyjphae extract can significantly reduce serum lactic acid behind the dog coronary ligation; the degree that creatine kinase raises; point out it can reduce acute ischemia myocardial cell CK; overflowing of lactic acid; primary cellular defect when alleviating myocardial ischemia has provide protection to the myocardial cell.
Two, Pollen Tyjphae extract is to the influence of anesthetized dog myocardial consumption of oxygen
1 materials and methods
1.1 animal
Healthy hybrid dog is provided by the The 2nd Army Medical College animal center, animal rearing conformity certification number: the moving word of medical officer D2001-31 number.Male female dual-purpose.11～13kg。Article 15,, be divided into 3 groups at random, 5 every group.
1.2 the dosage setting sees Table 6
Table 6 is respectively organized dosage, and that table group route of administration dosage number of animals (bar) physiological saline control group is set is oral, single-dose 1ml/kg 5 Fructus Hippophae total flavones groups are oral, single-dose 24mg/kg 5 Pollen Tyjphae extract groups are oral, single-dose 8mg/kg 5
1.3 test method
With reference to the method for Xu Shuyun (Xu Shuyun etc., chief editor. pharmacological experimental methodology (third edition). the 8th piece: the medicine for cardiovascular system laboratory method.Beijing: the People's Health Publisher, 2002:1054).Anesthetized dog separates right common femoral artery, is equipped with arterial blood gas analysis.Expose heart, make the pericardium bed, free root of ascending aorta and ramus descendens anterior arteriae coronariae sinistrae top are placed the magnetic flow meter probe (MFV-1100/1200 type, Japanese Nihon Kohden company) of suitable internal diameter respectively and are surveyed coronary flow.Separate right external jugular vein, guiding cardiac catheterization coronary sinus vein, heart catheter.Extract coronary sinus and femoral artery blood specimen (0.5% anticoagulant heparin) synchronously, (DH-1830 type vim and vigour acid alkali analyser, Nanjing analytical instrument factory) measures pO2 with Bloodgas Analyzer, and pH is converted into artery and venous oxygen content.When experiment finishes heart is weighed, and be poured into the electromagnetic flowmeter survey position with lower area with the senior burnt black ink adverse current in 10-15ml10% Shanghai, cutting-out is dyed the black area and is weighed, and is used for the calculating myocardium oxygen-consumption.Formula is: myocardial consumption of oxygen (ml/min/100g)=coronary flow ml/min/100g * (arterial blood oxygen ml%-coronary sinus blood oxygen ml%).
Experimental data is represented with x ± s, carries out variance analysis with SPSS 10.0 softwares, does test of significance.
2 results
Pollen Tyjphae extract to the influence of dog myocardial consumption of oxygen see Table 7 and Fig. 3 table 7 Pollen Tyjphae extract to dog myocardial consumption of oxygen (mL/min.100g
-1) influence (x ± s, n=5)
After the administration before the administration of group index
30min 60min 90min 120min physiological saline x ± S 204.6 ± 9.3 210.1 ± 9.4 205.2 ± 5.4 205.2 ± 5.5 212.8 ± 4.81ml/kg changes % 2.8 ± 5.5 0.4 ± 4.2 0.4 ± 3.1 4.2 ± 4.9 total seabuckthorn flavone x ± S 213.7 ± 5.8 191.5 ± 10.7△ △ △186.4 ± 9.4
△ △ △188.2 ± 9.4
△ △ △189.9 ± 8.5
△ △24mg/kg changes %-10.4 ± 4.4
* *-12.7 ± 3.8
* *-12.0 ± 2.2
* *-11.1 ± 3.6
* *Pollen Tyjphae extract x ± S 214.0 ± 10.0 183.7 ± 12.2
△ △179.3 ± 9.1
△ △ △182.7 ± 12.3
△ △191.5 ± 14.08mg/kg changes %-14.2 ± 3.1
* *-16.1 ± 4.9
* *-14.4 ± 8.3
* *-10.3 ± 7.7
* * △ △P＜0.05,
△ △ △P＜0.01 is relatively preceding with administration;
*P＜0.05,
* *Compare with the physiological saline group P＜0.01
From table 7, Fig. 3 as can be seen, Pollen Tyjphae extract 8mg/kg irritates behind the stomach myocardial consumption of oxygen and compares to some extent with the physiological saline group and descend, and each time point myocardial consumption of oxygen velocity of variation and physiological saline group were than difference remarkable (P＜0.01) since 30 minutes to 120 minutes.Fructus Hippophae total flavones can significantly reduce myocardial consumption of oxygen, and reduced rate is compared with time point with the physiological saline group, 30-120 minute significant difference (P＜0.01).
Pollen Tyjphae extract is to the influence of dog cardiac muscle oxygen uptake rate, sees Table 8 and Fig. 4
Table 8 Pollen Tyjphae extract to the influence of dog cardiac muscle oxygen uptake rate (%) (x ± s, n=5)
After the administration before the administration of group index
30min 60min 90min 120min physiological saline x ± S 84.6 ± 3.7 86.9 ± 2.6 85.6 ± 1.6 86.8 ± 2.2 89.4 ± 2.51ml/kg changes % 2.9 ± 4.6 1.3 ± 2.9 2.7 ± 2.6 5.7 ± 2.3 total seabuckthorn flavone x ± S 79.8 ± 5.3 66.2 ± 5.6 65.1 ± 6.1 65.7 ± 2.9 68.5 ± 5.624mg/kg and changes %-17.1 ± 4.2* *-18.5 ± 4.2
* *-17.5 ± 2.0
* *-14.2 ± 3.1
* *Pollen Tyjphae extract x ± S 79.6 ± 7.6 62.9 ± 7.2
△ △63.5 ± 7.1
△ △66.2 ± 6.8 70.7 ± 6.98mg/kg change %-21.1 ± 3.0
* *-20.3 ± 3.7
* *-16.6 ± 7.5
* *-10.9 ± 7.1
* * △ △P＜0.05,
△ △ △P＜0.01 is relatively preceding with administration;
*P＜0.05,
* *Compare with the physiological saline group P＜0.01
From table 8 and Fig. 4 as can be seen, Pollen Tyjphae extract can significantly reduce myocardium oxygen uptake rate after irritating stomach; Reduced rate is compared with time point with the physiological saline group, the equal highly significant of each time point difference (P＜0.01) from 30 minutes to 120 minutes, and the positive control drug Fructus Hippophae total flavones can significantly reduce myocardium oxygen uptake rate.
Pollen Tyjphae extract is to the influence of dog coronary flow, sees Table 9 and Fig. 5
Table 9 Pollen Tyjphae extract to the influence of dog coronary flow (ml/min) (x ± s, n=5)
After the administration before the administration of group index
30min 60min 90min 120min physiological saline x ± S 41.4 ± 8.6 41.4 ± 8.3 41.2 ± 8.4 40.8 ± 8.7 41.0 ± 8.21ml/kg changes % 0.2 ± 2.5-2.4 ± 0.8-1.6 ± 1.4-0.7 ± 2.3 total seabuckthorn flavone x ± S 44.2 ± 10.2 47.6 ± 10.4 47.2 ± 10.4 47.0 ± 10.6 45.6 ± 10.224mg/kg and changes % 8.0 ± 2.2* *7.0 ± 2.3
* *6.5 ± 0.8
* *3.3 ± 1.4 Pollen Tyjphae extract x ± S 42.4 ± 10.4 45.8 ± 10.1 44.4 ± 10.7 43.4 ± 10.5 42.6 ± 10.88mg/kg change % 8.6 ± 3.3
* *4.8 ± 2.3
*2.5 ± 1.5 0.3 ± 2.1
△ △P＜0.05 is relatively preceding with administration;
*P＜0.05,
* *Compare with the physiological saline group P＜0.01
From table 9 and Fig. 5 as can be seen, Pollen Tyjphae extract can increase coronary flow; Increment rate is compared with time point with the physiological saline group, and at 30,60 minutes significant differences (P＜0.05), the positive control drug Fructus Hippophae total flavones also can obviously increase coronary flow, and action time was from 30-90 minute.
Therefore Pollen Tyjphae extract can obviously increase the anesthetized dog coronary flow, obviously reduces myocardium oxygen uptake rate, significantly reduces myocardial consumption of oxygen, therefore can be used for preparing the medicine or the food of control myocardial ischemia cardiovascular disorder.
Claims (14)
1. a Pollen Tyjphae extract preparation method comprises the steps:
(1) extracts
Cattail pollen after extracting with the aqueous ethanol heating concentrates extracting solution, and supernatant liquor or filtrate are got in the centrifugal or filtration of concentrated solution;
(2) purifying
With centrifuged supernatant or filtered liquid macroporous resin adsorption, remove impurity with water wash earlier, use moisture lower alcohol wash-out again; Elutriant is concentrated into certain volume, uses the ethanol alcohol precipitation, goes post precipitation to be concentrated into to do or remove spraying drying behind the ethanol, Pollen Tyjphae extract.
2. Pollen Tyjphae extract preparation method according to claim 1 is characterized in that said macroporous resin is a polystyrene type porousness polymeric adsorbent.
3. Pollen Tyjphae extract preparation method according to claim 1 is characterized in that said lower alcohol is C
1～C
5Lower alcohol.
4. according to claim 1,2,3 described Pollen Tyjphae extract preparation methods, it is characterized in that said moisture concentration of lower alcohols is 40～95%.
5. according to claim 1,2,3 described Pollen Tyjphae extract preparation methods, it is characterized in that the ethanol final concentration with the ethanol alcohol precipitation is 70%～95%.
6. Pollen Tyjphae extract preparation method according to claim 4 is characterized in that the ethanol final concentration with the ethanol alcohol precipitation is 70%～95%.
7. claim 1,2,3, the prepared Pollen Tyjphae extract of 6 described Pollen Tyjphae extract preparation methods.
8. the prepared Pollen Tyjphae extract of the described Pollen Tyjphae extract preparation method of claim 4.
9. the prepared Pollen Tyjphae extract of the described Pollen Tyjphae extract preparation method of claim 5.
10. Pollen Tyjphae extract according to claim 7 is characterized in that general flavone content is more than 50%.
11. according to Claim 8,9 described Pollen Tyjphae extracts, it is characterized in that general flavone content is more than 50%.
12. the described Pollen Tyjphae extract of claim 7 is used to prepare the purposes of control myocardial ischemia cardiovascular disease medicine or food.
13. claim 8,9,10 described Pollen Tyjphae extracts are used to prepare the purposes of control myocardial ischemia cardiovascular disease medicine or food.
14. the described Pollen Tyjphae extract of claim 11 is used to prepare the purposes of control myocardial ischemia cardiovascular disease medicine or food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031155081A CN1188406C (en) | 2003-02-25 | 2003-02-25 | Cattail pollen extract and preparation process and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031155081A CN1188406C (en) | 2003-02-25 | 2003-02-25 | Cattail pollen extract and preparation process and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1434042A true CN1434042A (en) | 2003-08-06 |
| CN1188406C CN1188406C (en) | 2005-02-09 |
Family
ID=27634261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031155081A Expired - Fee Related CN1188406C (en) | 2003-02-25 | 2003-02-25 | Cattail pollen extract and preparation process and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1188406C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006097940A1 (en) * | 2005-03-14 | 2006-09-21 | Johnson & Johnson Limited | A bandage with enhanced hemostatic effect |
| CN1315861C (en) * | 2004-12-24 | 2007-05-16 | 北京中医药大学 | Process for extracting and separating isorhamnetin -3-o-neohesperidoside from cattail pollen |
| CN1315856C (en) * | 2004-12-24 | 2007-05-16 | 北京中医药大学 | Extraction and separation method of cattail new glycoside in cattail polleo |
| CN100366630C (en) * | 2005-01-20 | 2008-02-06 | 安徽科创中药天然药物研究所有限责任公司 | Preparation of suaveolic flavone for treating chronic pharyngitis and chronic tonsilltiis |
| CN101073623B (en) * | 2006-05-18 | 2011-08-10 | 天津天士力制药股份有限公司 | Method for separating and extracting cattail pollen |
| CN102949535A (en) * | 2011-08-29 | 2013-03-06 | 苏州同立医药技术有限公司 | Chinese herbal preparation resistant to hyperlipidemia and atherosclerosis and preparation method of Chinese herbal preparation |
| CN116077570A (en) * | 2023-02-02 | 2023-05-09 | 河北瑞龙生物科技有限公司 | Preparation method of pollen typhae extract |
-
2003
- 2003-02-25 CN CNB031155081A patent/CN1188406C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315861C (en) * | 2004-12-24 | 2007-05-16 | 北京中医药大学 | Process for extracting and separating isorhamnetin -3-o-neohesperidoside from cattail pollen |
| CN1315856C (en) * | 2004-12-24 | 2007-05-16 | 北京中医药大学 | Extraction and separation method of cattail new glycoside in cattail polleo |
| CN100366630C (en) * | 2005-01-20 | 2008-02-06 | 安徽科创中药天然药物研究所有限责任公司 | Preparation of suaveolic flavone for treating chronic pharyngitis and chronic tonsilltiis |
| WO2006097940A1 (en) * | 2005-03-14 | 2006-09-21 | Johnson & Johnson Limited | A bandage with enhanced hemostatic effect |
| CN101073623B (en) * | 2006-05-18 | 2011-08-10 | 天津天士力制药股份有限公司 | Method for separating and extracting cattail pollen |
| CN102949535A (en) * | 2011-08-29 | 2013-03-06 | 苏州同立医药技术有限公司 | Chinese herbal preparation resistant to hyperlipidemia and atherosclerosis and preparation method of Chinese herbal preparation |
| CN116077570A (en) * | 2023-02-02 | 2023-05-09 | 河北瑞龙生物科技有限公司 | Preparation method of pollen typhae extract |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1188406C (en) | 2005-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102600219B (en) | Total flavone extract of abelmoschus manihot and preparing method of total flavone extract | |
| CN102908583B (en) | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation method, quality detection method and application of composition | |
| US20040162246A1 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same | |
| CN107441078B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN104435034A (en) | PNS (panax notoginseng saponins) and preparation method thereof | |
| CN103349671A (en) | Resveratrol and spirulina composition and preparations and preparation method thereof | |
| CN1434042A (en) | Cattail pollen extract and preparation process and use thereof | |
| CN108379404A (en) | A kind of extraction purification technology of neural cell injury repair medicine | |
| CN102614276A (en) | Dahurian rose fruit leaf general flavone extract, and extracting method and medical application thereof | |
| CN101623437B (en) | Pulse-activating preparation for injection and preparation method thereof | |
| CN102100737B (en) | Medicinal composition containing general ginsenoside and total salvianolic acid and preparation method thereof | |
| CN1927324A (en) | Preparation method of traditional medicine preparation for treating women's menoxenia | |
| CN1931233B (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
| CN105687262A (en) | Folium ginkgo tincture and preparing method thereof | |
| CN103432420B (en) | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method | |
| CN108065393A (en) | A kind of food or health food prevented and treat cardiovascular and cerebrovascular disease | |
| CN101049355B (en) | Composition of medication prepared from safflower and leaves of hawthorn | |
| CN101028437A (en) | Chinese-medicinal effective part composition for preventing cardiovascular disease and its production | |
| CN1068790C (en) | Medicinal composition containing total saponin extracted from stem and leaves of American ginseng | |
| CN1468860A (en) | Manyprickle acanthopanax general saponin extractive and its medicinal composition | |
| CN102716231B (en) | A kind of Chinese medicine composition and application thereof for the treatment of brain injury and cerebral edema | |
| CN102018740B (en) | Medicinal composition containing extracts of leaves of helianthus and application of the same | |
| CN101129604B (en) | Antihypelipidemic traditional Chinese medicine producing method | |
| CN105616556B (en) | A kind of preparation method preventing and treating alcoholic liver injury active principle | |
| CN104586925B (en) | Redback christmashush root extract and preparation method and preparation treatment hepatitis B medicine application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050209 |